Loading...

Monash IVF Group

DB:MIS
Snowflake Description

Average dividend payer and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MIS
DB
A$251M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
MIS Share Price and Events
7 Day Returns
1.1%
DB:MIS
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-6.7%
DB:MIS
-10.2%
DE Biotechs
-6%
DE Market
MIS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Monash IVF Group (MIS) 1.1% -0.6% 13.9% -6.7% -44.8% -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • MIS outperformed the Biotechs industry which returned -10.2% over the past year.
Price Volatility
MIS
Industry
5yr Volatility vs Market

Value

 Is Monash IVF Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Monash IVF Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Monash IVF Group.

DB:MIS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:MIS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 30%) (37%))
1.551
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.55
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.551 * 5.96%)
9.47%

Discounted Cash Flow Calculation for DB:MIS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Monash IVF Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:MIS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 9.47%)
2019 21.00 Analyst x1 19.18
2020 22.00 Analyst x1 18.36
2021 22.00 Analyst x1 16.77
2022 22.39 Analyst x1 15.59
2023 22.68 Est @ 1.3% 14.43
2024 22.90 Est @ 0.98% 13.31
2025 23.08 Est @ 0.75% 12.25
2026 23.21 Est @ 0.6% 11.25
2027 23.33 Est @ 0.49% 10.33
2028 23.42 Est @ 0.41% 9.47
Present value of next 10 years cash flows A$140.93
DB:MIS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$23.42 × (1 + 0.23%) ÷ (9.47% – 0.23%)
A$253.92
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$253.92 ÷ (1 + 9.47%)10
A$102.71
DB:MIS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$140.93 + A$102.71
A$243.64
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$243.64 / 235.58
A$1.03
DB:MIS Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:MIS represents 0.61596x of ASX:MVF
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.61596x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (AUD) x Listing Adjustment Factor
= A$ 1.03 x 0.61596
€0.64
Value per share (EUR) From above. €0.64
Current discount Discount to share price of €0.66
= -1 x (€0.66 - €0.64) / €0.64
-3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Monash IVF Group is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Monash IVF Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Monash IVF Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MIS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$0.08
ASX:MVF Share Price ** ASX (2019-04-18) in AUD A$1.07
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Monash IVF Group.

DB:MIS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:MVF Share Price ÷ EPS (both in AUD)

= 1.07 ÷ 0.08

13.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Monash IVF Group is good value based on earnings compared to the Europe Biotechs industry average.
  • Monash IVF Group is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Monash IVF Group's expected growth come at a high price?
Raw Data
DB:MIS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 13.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
4.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

DB:MIS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 13.22x ÷ 4.5%

2.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Monash IVF Group is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Monash IVF Group's assets?
Raw Data
DB:MIS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.72
ASX:MVF Share Price * ASX (2019-04-18) in AUD A$1.07
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:MIS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:MVF Share Price ÷ Book Value per Share (both in AUD)

= 1.07 ÷ 0.72

1.47x

* Primary Listing of Monash IVF Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Monash IVF Group is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Monash IVF Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Monash IVF Group has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Monash IVF Group expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
4.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Monash IVF Group expected to grow at an attractive rate?
  • Monash IVF Group's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Monash IVF Group's earnings growth is positive but not above the Germany market average.
  • Monash IVF Group's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:MIS Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MIS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 4.5%
DB:MIS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MIS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MIS Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-06-30 196 23 1
2021-06-30 171 28 22 3
2020-06-30 164 27 22 3
2019-06-30 158 29 20 3
DB:MIS Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 151 29 19
2018-09-30 151 28 20
2018-06-30 151 26 21
2018-03-31 152 24
2017-12-31 153 29 26
2017-09-30 154 28 28
2017-06-30 155 26 30
2017-03-31 156 30
2016-12-31 156 34 30
2016-09-30 156 39 29
2016-06-30 157 44 29
2016-03-31 150 41 27

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Monash IVF Group's earnings are expected to grow by 4.5% yearly, however this is not considered high growth (20% yearly).
  • Monash IVF Group's revenue is expected to grow by 6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MIS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Monash IVF Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MIS Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-06-30 0.10 0.10 0.10 1.00
2021-06-30 0.09 0.09 0.09 2.00
2020-06-30 0.09 0.09 0.09 2.00
2019-06-30 0.08 0.08 0.08 1.00
DB:MIS Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 0.08
2018-09-30 0.09
2018-06-30 0.09
2018-03-31 0.10
2017-12-31 0.11
2017-09-30 0.12
2017-06-30 0.13
2017-03-31 0.13
2016-12-31 0.13
2016-09-30 0.12
2016-06-30 0.12
2016-03-31 0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Monash IVF Group is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Monash IVF Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Monash IVF Group has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Monash IVF Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Monash IVF Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Monash IVF Group has delivered over 20% year on year earnings growth in the past 5 years.
  • Monash IVF Group's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Monash IVF Group's 1-year earnings growth is negative, it can't be compared to the Europe Biotechs industry average.
Earnings and Revenue History
Monash IVF Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Monash IVF Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MIS Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 150.86 18.97 17.06
2018-09-30 150.75 20.16 16.79
2018-06-30 150.64 21.35 16.53
2018-03-31 152.03 23.89 16.70
2017-12-31 153.43 26.43 16.47
2017-09-30 154.31 28.02 16.36
2017-06-30 155.18 29.62 16.25
2017-03-31 155.56 29.81 15.82
2016-12-31 155.93 30.01 15.39
2016-09-30 156.25 29.39 15.74
2016-06-30 156.56 28.78 16.09
2016-03-31 150.28 26.59 12.70
2015-12-31 144.00 24.40 9.31
2015-09-30 134.48 22.89 9.04
2015-06-30 124.96 21.37 8.76
2015-03-31 120.83 14.75 8.50
2014-12-31 116.71 8.13 8.23
2014-09-30 115.36 5.36 8.42
2014-06-30 114.01 2.58 8.60
2014-03-31 110.11 1.50 4.24
2013-12-31 106.21 0.42 -0.13
2013-09-30 101.40 -7.22 3.11
2013-06-30 96.60 -14.86 6.35
2012-06-30 93.24 -15.32 24.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Monash IVF Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Monash IVF Group used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Monash IVF Group's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Monash IVF Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Monash IVF Group has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Monash IVF Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Monash IVF Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Monash IVF Group's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Monash IVF Group's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Monash IVF Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Monash IVF Group Company Filings, last reported 3 months ago.

DB:MIS Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 170.55 92.84 4.60
2018-09-30 170.55 92.84 4.60
2018-06-30 166.86 98.11 3.85
2018-03-31 166.86 98.11 3.85
2017-12-31 165.47 99.95 5.79
2017-09-30 165.47 99.95 5.79
2017-06-30 163.52 95.66 3.50
2017-03-31 163.52 95.66 3.50
2016-12-31 159.61 96.79 4.18
2016-09-30 159.61 96.79 4.18
2016-06-30 154.88 95.00 8.47
2016-03-31 154.88 95.00 8.47
2015-12-31 149.37 104.15 10.62
2015-09-30 149.37 104.15 10.62
2015-06-30 144.03 106.99 9.99
2015-03-31 144.03 106.99 9.99
2014-12-31 135.39 89.24 5.26
2014-09-30 135.39 89.24 5.26
2014-06-30 124.82 95.54 8.79
2014-03-31 124.82 95.54 8.79
2013-12-31 35.24 205.81 35.23
2013-09-30 35.24 205.81 35.23
2013-06-30 -46.92 283.99 40.63
2012-06-30 -32.58 284.72 29.60
  • Monash IVF Group's level of debt (54.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (564.7% vs 54.4% today).
  • Debt is well covered by operating cash flow (31.4%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 9.1x coverage).
X
Financial health checks
We assess Monash IVF Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Monash IVF Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Monash IVF Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
5.26%
Current annual income from Monash IVF Group dividends. Estimated to be 6.13% next year.
If you bought €2,000 of Monash IVF Group shares you are expected to receive €105 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Monash IVF Group's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.43%).
  • Monash IVF Group's dividend is above the markets top 25% of dividend payers in Germany (3.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MIS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MIS Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2022-06-30 0.07 1.00
2021-06-30 0.07 3.00
2020-06-30 0.06 3.00
2019-06-30 0.06 3.00
DB:MIS Past Annualized Dividends Data
Date (Data in A$) Dividend per share (annual) Avg. Yield (%)
2019-02-25 0.056 5.234
2018-08-27 0.060 6.053
2018-02-26 0.079 6.840
2017-08-21 0.088 6.281
2017-02-20 0.058 3.212
2016-08-25 0.090 4.383
2016-02-25 0.080 4.236
2015-08-28 0.074 5.231
2015-02-24 0.065 4.607

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Monash IVF Group has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Monash IVF Group has only been paying a dividend for 4 years, and since then dividends per share have fallen.
Current Payout to shareholders
What portion of Monash IVF Group's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.4x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be covered by earnings (1.3x coverage).
X
Income/ dividend checks
We assess Monash IVF Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Monash IVF Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Monash IVF Group has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Monash IVF Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Knaap
COMPENSATION A$424,108
TENURE AS CEO 0.5 years
CEO Bio

Mr. Michael D. Knaap serves as Chief Executive Officer & Managing Director of Monash IVF Group Limited since April 15, 2019. Mr. Knaap served as an Interim Chief Executive Officer of Monash IVF Group Limited since October 9, 2018 until April 15, 2019 and served as its Group Chief Financial Officer since August 31, 2015 until January 2019 and served as its Company Secretary since August 31, 2015 until April 15, 2019. Mr. Knaap is an experienced senior healthcare executive with a strong operational, strategic and leadership background. Mr. Knaap served as the Chief Financial Officer of Patties Foods Limited from February 16, 2009 to July 31, 2015 and its Company Secretary from February 29, 2012 to June 4, 2015. He served as a Joint Acting Chief Executive of Patties Foods Limited from September 2013 to April 15, 2014 and served as its Executive Officer from June 4, 2015 to July 31, 2015. He also held a number of executive positions at Patties Foods Limited over the past six years. He has experience in senior finance executive roles in the FMCG sector in both listed and unlisted companies. He is a Certified Practising Accountant. He holds a Bachelor of Accounting from Monash University.

CEO Compensation
  • Michael's compensation has been consistent with company performance over the past year.
  • Michael's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Monash IVF Group management team in years:

1
Average Tenure
  • The average tenure for the Monash IVF Group management team is less than 2 years, this suggests a new team.
Management Team

Michael Knaap

TITLE
Interim CEO & Company Secretary
COMPENSATION
A$424K
TENURE
0.5 yrs

Brett Comer

TITLE
Chief Operations Officer
COMPENSATION
A$267K
TENURE
1 yrs

Richard Henshaw

TITLE
Executive Director
COMPENSATION
A$383K

Malik Jainudeen

TITLE
CFO & Company Secretary
TENURE
0.3 yrs

Pierre Haila

TITLE
Chief Information Officer
TENURE
1.3 yrs

Everard Hunder

TITLE
General Manager of Marketing

Peggy North

TITLE
Chief People & Culture Officer

Clementina Singh

TITLE
General Manager of New South Wales
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Monash IVF Group board of directors in years:

4.8
Average Tenure
63
Average Age
  • The tenure for the Monash IVF Group board of directors is about average.
Board of Directors

Richard Davis

TITLE
Independent Chairman
COMPENSATION
A$156K
AGE
63
TENURE
4.8 yrs

Richard Henshaw

TITLE
Executive Director
COMPENSATION
A$383K
TENURE
5 yrs

Joe Czyzewski

TITLE
Independent Non-Executive Director
COMPENSATION
A$111K
AGE
67
TENURE
4.8 yrs

Christy Boyce

TITLE
Independent Non-Executive Director
COMPENSATION
A$111K
TENURE
4.8 yrs

Neil Broekhuizen

TITLE
Non-Executive Director
COMPENSATION
A$95K
TENURE
4.8 yrs

Zita Peach

TITLE
Independent Non-Executive Director
COMPENSATION
A$95K
AGE
53
TENURE
2.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Mar 19 Sell Adam Smith Asset Management Pty Limited Company 28. Nov 17 28. Feb 19 -2,908,688 €0.69 €-2,012,367
04. Mar 19 Buy Adam Smith Asset Management Pty Limited Company 28. Nov 17 28. Feb 19 5,955,656 €0.70 €4,179,655
27. Nov 18 Buy Richard Henshaw Individual 23. Nov 18 23. Nov 18 303,030 €0.63 €190,509
25. Oct 18 Buy Christina Mary Boyce Individual 19. Oct 18 22. Oct 18 40,000 €0.59 €23,237
18. Oct 18 Sell BT Funds Management (NZ) Limited Company 19. Sep 17 06. Jun 18 -551,687 €0.71 €-393,576
18. Oct 18 Buy BT Funds Management (NZ) Limited Company 22. Feb 18 16. Oct 18 2,933,123 €0.68 €1,995,500
18. Oct 18 Buy Richard Davis Individual 17. Oct 18 17. Oct 18 25,773 €0.60 €15,429
16. Oct 18 Buy Christina Mary Boyce Individual 10. Oct 18 10. Oct 18 10,000 €0.58 €5,832
16. Oct 18 Buy Josef Czyzewski Individual 10. Oct 18 10. Oct 18 20,000 €0.59 €11,748
12. Oct 18 Buy Zita Peach Individual 11. Oct 18 11. Oct 18 27,260 €0.58 €15,832
X
Management checks
We assess Monash IVF Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Monash IVF Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. It provides fertility research and treatment services, tertiary level prenatal diagnostic services, low intervention IVF services, and diagnostic ultrasound services. The company operates 22 fertility clinics, 18 specialist women’s imaging sites, 5 service centers, 2 specialized diagnostic laboratories, and 3 day hospitals. The company was incorporated in 2014 and is based in Richmond, Australia.

Details
Name: Monash IVF Group Limited
MIS
Exchange: DB
Founded: 2014
A$159,501,452
235,580,943
Website: http://www.monashivfgroup.com.au
Address: Monash IVF Group Limited
Pelaco Building 1,
Level 1,
Richmond,
Victoria, 3121,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX MVF Ordinary Shares Australian Securities Exchange AU AUD 26. Jun 2014
DB MIS Ordinary Shares Deutsche Boerse AG DE EUR 26. Jun 2014
CHIA MVF Ordinary Shares Chi-X Australia AU AUD 26. Jun 2014
Number of employees
Current staff
Staff numbers
588
Monash IVF Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:43
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/02/25
Last earnings filing: 2019/02/24
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.